Treatment of abnormal uterine bleeding

The treatment of abnormal uterine bleeding (“AUB”), and postpartum hemorrhage (“PPH”), are two of the most dramatic areas of critical unmet need in women’s health. AUB is a broad term that describes irregularities involving frequency, regularity, duration, and volume of uterine blood loss outside of pregnancy. Up to one third of women will experience AUB in their life, with irregularities most commonly occurring at the start ofmenstruation and perimenopause. PPH is a leading cause of maternal mortality. Despite the remarkable prevalence of AUB and PPH, serious gaps in care persist for both. There are no US-FDA approved drugs for the acute management of AUB, and surgical management severely impacts fertility. For women experiencing PPH, the condition is life threatening.Avana’s treatment is designed to directly address blood loss via the exposed or damaged blood vessels, take effect much faster than existing treatments, and provide benefit for longer than other single dose therapeutics without the negative impact to fertility that comes with surgical options (e.g., hysterectomy). This trial seeks to develop additional safety and bioavailability data from women actively experiencing blood loss.